Nykode Therapeutics (OB:NYKD) - Hisse Senedi Fiyatı, Haberler ve Analizler

NYKD Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Nykode Therapeutics AS, yeni immünoterapiler keşfetmekte ve geliştirmektedir.

Şirket hakkında

NYKD temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 22.75% oranında artması öngörülüyor

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 20.7% oranında düşmesi öngörülüyor

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Hissedarlar geçen yıl sulandırıldı

Nykode Therapeutics AS Rakipler

ArcticZymes Technologies

OB:AZT

NOK 858.0m

Hofseth BioCare

OB:HBC

NOK 661.8m

Lytix Biopharma

OB:LYTIX

NOK 302.6m

PCI Biotech Holding

OB:PCIB

NOK 64.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Nykode Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	NOK 5.29
52 Haftanın En Yüksek Seviyesi	NOK 21.62
52 Haftanın En Düşük Seviyesi	NOK 4.37
Beta	1.34
11 Aylık Değişim	-3.64%
3 Aylık Değişim	-63.52%
1 Yıllık Değişim	-73.01%
33 Yıllık Değişim	-91.84%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-73.28%

Son Haberler & Güncellemeler

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Aug 05

Recent updates

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Aug 05

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 02

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Jan 22

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Aug 20

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Apr 06

Could The Vaccibody AS (OB:VACC) Ownership Structure Tell Us Something Useful?

Jan 25

Hissedar Getirileri

	NYKD	NO Biotechs	NO Pazar
7D	3.9%	-5.0%	-1.3%
1Y	-73.0%	-58.2%	2.2%

Getiri vs. Endüstri: NYKD geçen yıl % -60.9 oranında getiri sağlayan Norwegian Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: NYKD geçen yıl % 3.2 oranında getiri sağlayan Norwegian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is NYKD's price volatile compared to industry and market?
NYKD volatility
NYKD Average Weekly Movement	16.8%
Biotechs Industry Average Movement	10.8%
Market Average Movement	4.9%
10% most volatile stocks in NO Market	10.6%
10% least volatile stocks in NO Market	2.7%

İstikrarlı Hisse Senedi Fiyatı: NYKD hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: NYKD 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 11% dan 16% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2006	179	Michael Engsig	nykode.com

Klinik aşamada bir biyofarmasötik şirketi olan Nykode Therapeutics AS, yeni immünoterapiler keşfetmekte ve geliştirmektedir. Şirket, kanser ve bulaşıcı hastalıkların tedavisi için aşılar geliştirmektedir. Öncü ürün adayları arasında melanom, akciğer, mesane, böbrek, baş ve boyun kanserinin tedavisi için faz I/IIa klinik çalışmasında olan bir kanser neoantijen aşısı olan VB10

Nykode Therapeutics AS Temel Bilgiler Özeti

Nykode Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NYKD temel i̇stati̇sti̇kler
Piyasa değeri	NOK 1.73b
Kazançlar(TTM)	-NOK 413.37m
Gelir(TTM)	NOK 71.04m

24.3x

P/S Oranı

-4.2x

F/K Oranı

NYKD aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NYKD gelir tablosu (TTM)
Gelir	US$6.52m
Gelir Maliyeti	US$0
Brüt Kâr	US$6.52m
Diğer Giderler	US$44.43m
Kazançlar	-US$37.91m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 27, 2024

Hisse başına kazanç (EPS)	-0.12
Brüt Marj	100.00%
Net Kâr Marjı	-581.88%
Borç/Özkaynak Oranı	0%

NYKD uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

NYKD Stoklara Genel Bakış

Ödüller

Risk Analizi

Nykode Therapeutics AS Rakipler

OB:AZT

NOK 858.0m

OB:HBC

NOK 661.8m

OB:LYTIX

NOK 302.6m

OB:PCIB

NOK 64.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Consensus revenue estimates decrease by 19%

Price target decreased by 20% to kr29.13

Consensus revenue estimates decrease by 54%, EPS upgraded

Chairman of the Board recently bought kr283k worth of stock

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Recent updates

Consensus revenue estimates decrease by 19%

Price target decreased by 20% to kr29.13

Consensus revenue estimates decrease by 54%, EPS upgraded

Chairman of the Board recently bought kr283k worth of stock

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

New minor risk - Share price stability

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting

Consensus revenue estimates decrease by 35%, EPS upgraded

Consensus revenue estimates increase by 37%, EPS downgraded

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Director recently bought kr310k worth of stock

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases

Price target decreased by 36% to kr43.00

Consensus EPS estimates upgraded to US$0.18 loss

Chief Executive Officer recently bought kr100k worth of stock

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Nykode Therapeutics AS to Report Q4, 2024 Results on Feb 26, 2025

Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer

Third quarter 2023 earnings released: US$0.03 loss per share (vs US$0.05 loss in 3Q 2022)

New minor risk - Shareholder dilution

Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer

Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research

Nykode Therapeutics ASA Announces FDA Approval of IND for VB-C-04, a Trial of VB-C-04 in HPV16-Positive Cervical Cancer

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the Next Trial in Advanced Cervical Cancer

Nykode Therapeutics AS Announces Management Changes

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Full year 2022 earnings released: US$0.15 loss per share (vs US$0.033 loss in FY 2021)

Director exercised options and sold kr7.4m worth of stock

Nykode Therapeutics AS to Report Q3, 2023 Results on Nov 15, 2023

Nykode Expands Clinical Development Plan for Its Lead Cancer Vaccine Vb10.16 in Hpv16-Positive Cancers

Third quarter 2022 earnings released: US$0.05 loss per share (vs US$0.03 loss in 3Q 2021)

No independent directors

Nykode Therapeutics Presents Additional Efficacy Analysis in Phase 2 Study of VB10.16 in Combination with Atezolizumab in Advanced Cervical Cancer

Nykode Therapeutics ASA Announces Presentation of Positive Immunogenicity Results from Phase 1/2A Study of VB10.NEO

Nykode Therapeutics ASA Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate

Second quarter 2022 earnings released: US$0.03 loss per share (vs US$0.02 loss in 2Q 2021)

Nykode Therapeutics Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial

Nykode Therapeutics AS Appoints Klaus Edvardsen as Chief Development Officer, Effective from July 1, 2022

Chairman of the Board recently bought kr321k worth of stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Nykode Therapeutics AS Appoints Elaine Sullivan and Anne Whitaker to the Board of Directors

Nykode Therapeutics AS Announces Positive Interim Results from Its Phase 2 Trial with VB10.16 in Combination with Immune Checkpoint Inhibitor Atezolizumab in Advanced Cervical Cancer

No independent directors

Nykode Therapeutics as Announces Presentation of Preclinical Data from Its Second Generation Vaccibody Vaccine Technology At 2022 American Association for Cancer Research (AACR) Annual Meeting

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Nykode Therapeutics Announces Completion of Patient Enrollment in Its Phase 2 Trial of Vb10.16 in Combination with Atezolizumab for the Treatment of Advanced Cervical Cancer

Investor sentiment deteriorated over the past week

Nykode Therapeutics AS Announces First Subject Dosed with Its T Cell Focused Next-Generation SARS-CoV-2 Vaccine Candidate